Structure of Ro 48-8071 fumarate
CAS No.: 189197-69-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 189197-69-1 |
Formula : | C27H31BrFNO6 |
M.W : | 564.44 |
SMILES Code : | O=C(C1=CC=C(OCCCCCCN(CC=C)C)C=C1F)C2=CC=C(Br)C=C2.O=C(O)/C=C/C(O)=O |
MDL No. : | MFCD05865242 |
InChI Key : | XCYAYLWZCRGKDS-WLHGVMLRSA-N |
Pubchem ID : | 9959583 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Human umbilical vein endothelial cells (HUVECs) | 1 µM | 18-24 hours | To evaluate the effect of Ro 48-8071 on endothelial cell migration and adhesion. Results showed that Ro 48-8071 significantly inhibited both VEGF-induced and baseline EC migration (by 52% and 57%, respectively) and significantly inhibited EC adhesion to different extracellular matrices (e.g., vitronectin, fibronectin, and collagen I) (by 61%, 58%, and 52%, respectively). Additionally, Ro 48-8071 significantly suppressed tube formation in the Matrigel assay (by 70%). | Sci Rep. 2015 Mar 12;5:9054 |
Normal AG11132A mammary cells | up to 10 µM | 24 hours | To determine the effect of RO 48-8071 on the viability of normal mammary cells, concentrations up to 10 μM had no effect on normal cells. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
Neonatal mouse oligodendrocyte precursor cells | 10 nM | 24 hours | Ro 48-8071 blocked TF-induced oligodendrocyte differentiation and inhibited TF-induced zymosterol accumulation | Neurol Neuroimmunol Neuroinflamm. 2021 Oct 12;8(6):e1091. |
HepG2 cells | 0.113 µM (EC50) | 24 hours | To evaluate the effects of Ro 48-8071 on PXR-responsive reporter expression. Results showed that Ro 48-8071 significantly activated PXR-responsive reporter expression. | Drug Metab Dispos. 2009 Apr;37(4):900-8. |
Primary cultured human hepatocytes | 3, 10, 30 µM | 24 hours | To evaluate the effects of Ro 48-8071 on CYP3A4 and CYP2B6 mRNA content. Results showed that Ro 48-8071 treatment significantly increased CYP3A4 and CYP2B6 mRNA levels. | Drug Metab Dispos. 2009 Apr;37(4):900-8. |
ZR-75 cells | 11.04 ± 0.29 µM (24 h), 7.63 ± 0.30 µM (48 h) | 24 hours and 48 hours | To determine the effect of RO 48-8071 on the viability of ZR-75 cells, the IC50 values were found to be 11.04 ± 0.29 μM at 24 h and 7.63 ± 0.30 μM at 48 h. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
HCC-1428 cells | 14.64 ± 0.42 µM (24 h), 11.58 ± 0.34 µM (48 h) | 24 hours and 48 hours | To determine the effect of RO 48-8071 on the viability of HCC-1428 cells, the IC50 values were found to be 14.64 ± 0.42 μM at 24 h and 11.58 ± 0.34 μM at 48 h. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
MCF-7 cells | 12.32 ± 0.59 µM (24 h), 6.34 ± 0.34 µM (48 h) | 24 hours and 48 hours | To determine the effect of RO 48-8071 on the viability of MCF-7 cells, the IC50 values were found to be 12.32 ± 0.59 μM at 24 h and 6.34 ± 0.34 μM at 48 h. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
T47-D cells | 11.53 ± 0.36 µM (24 h), 7.76 ± 0.29 µM (48 h) | 24 hours and 48 hours | To determine the effect of RO 48-8071 on the viability of T47-D cells, the IC50 values were found to be 11.53 ± 0.36 μM at 24 h and 7.76 ± 0.29 μM at 48 h. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
BT-474 cells | 9.51 ± 0.05 µM (24 h), 6.06 ± 0.23 µM (48 h) | 24 hours and 48 hours | To determine the effect of RO 48-8071 on the viability of BT-474 cells, the IC50 values were found to be 9.51 ± 0.05 μM at 24 h and 6.06 ± 0.23 μM at 48 h. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
PANC-1 cells | 1, 3, 10, 30, 100 µM | 24, 48, 72 hours | RO inhibited PANC-1 cell viability in a dose- and time-dependent manner. The inhibitory ratio was approximately 40% at 10 µM after 72 h and 80% at 30 and 100 µM. | Mol Med Rep. 2021 Dec;24(6):828 |
KLE cells | 6.478 µM (IC50) | 48 hours | Ro 48-8071 significantly inhibited EC cell proliferation | Cell Death Discov. 2025 Feb 8;11(1):55 |
Ishikawa cells | 0.968 µM (IC50) | 48 hours | Ro 48-8071 significantly inhibited EC cell proliferation | Cell Death Discov. 2025 Feb 8;11(1):55 |
Plasmodium falciparum 3D7 clone | 4.5 ± 0.3 µM (IC50) | 48 hours | Ro 48-8071 significantly inhibited MQ-4 biosynthesis, reducing it by 88.2 ± 11%, while UQ increased by 30 ± 5%. | FEBS Lett. 2010 Dec 1;584(23):4761-4768 |
Helix lucorum neurons | 2 µM | 60 minutes | Ro 48-8071 2 μM decreased the average rate of ACh-induced current depression and did not change the level of spontaneous recovery. The ACh-current amplitude declined constantly in time and did not reach the steady-state level. | Cell Mol Neurobiol. 2017 Nov;37(8):1443-1455 |
Pancreatic ductal adenocarcinoma cells (HPAF-II) | 1 µM | 9 hours | To evaluate the effect of Ro 48-8071 on Akt and ERK phosphorylation in HPAF-II cells. Results showed that Ro 48-8071 significantly inhibited Akt and ERK phosphorylation. | Sci Rep. 2015 Mar 12;5:9054 |
Colon cancer cells (HCT116) | 1 µM | 9 hours | To evaluate the effect of Ro 48-8071 on Akt and ERK phosphorylation in HCT116 cells. Results showed that Ro 48-8071 significantly inhibited Akt and ERK phosphorylation. | Sci Rep. 2015 Mar 12;5:9054 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | RIP-Tag2 transgenic mouse model (spontaneous neuroendocrine pancreatic tumor model), HCT116 human colon carcinoma xenograft model, HPAF-II human pancreatic ductal adenocarcinoma xenograft model | Oral | 10 mg/kg/dayaily | Once daily for 4 weeks (RIP-Tag2 model) or 2 weeks (HCT116 and HPAF-II models) | To evaluate the effect of Ro 48-8071 on tumor growth, angiogenesis, and metastasis. Results showed that Ro 48-8071 significantly inhibited tumor growth in RIP-Tag2 mice (by 40%) and significantly reduced tumor volume in HCT116 and HPAF-II xenograft models (by 46% and 47%, respectively). Additionally, Ro 48-8071 significantly reduced lung metastasis in the HCT116 model (number and incidence reduced by 81% and 53%, respectively) and liver metastasis in the HPAF-II model (incidence and number reduced by 75% and 60%, respectively). Ro 48-8071 also significantly reduced tumor vessel area (by 49%, 67%, and 56% in RIP-Tag2, HCT116, and HPAF-II, respectively) and increased pericyte coverage (by 44%, 33%, and 31% in RIP-Tag2, HCT116, and HPAF-II, respectively). Furthermore, when combined with 5-fluorouracil (5-FU), Ro 48-8071 significantly enhanced anti-tumor and anti-metastatic effects (tumor growth inhibition by 71%, lung metastasis incidence and number reduced by 83% and 89%, respectively). | Sci Rep. 2015 Mar 12;5:9054 |
BALB/c mice | BALB/c mice | Oral | 20 mg/day/kg | Daily, for 7 to 21 days | Ro 48-8071 led to a rapid and sustained inhibition (>50%) of cholesterol synthesis in the small intestine. Hepatic cholesterol synthesis was markedly suppressed initially but rebounded to higher than baseline rates within 7 days. Whole body cholesterol synthesis, fractional cholesterol absorption, and fecal neutral and acidic sterol excretion were not consistently changed. | Biochem Pharmacol. 2014 Apr 1;88(3):351-63 |
Nude mice | Subcutaneous tumor model | Oral | 20 mg/kg | Once daily, during the experiment | Ro 48-8071 significantly inhibited xenograft tumor growth | Cell Death Discov. 2025 Feb 8;11(1):55 |
C57L/J mice | Cholesterol cholelithiasis model | Oral | 30-100 mg/kg/day | Once daily for 56 days | To assess the potential of Ro 48-8071 in preventing cholesterol cholelithiasis in C57L/J mice. Results showed that Ro 48-8071 significantly reduced gallstone prevalence and increased biliary phospholipid secretion rates. | Gut. 2004 Jan;53(1):136-42 |
BALB/c nude mice | Subcutaneous tumor xenograft model | Intravenous injection | 5 mg/kg/day | Once daily for the first 5 days, then once every other day for six more injections | RO significantly inhibited subcutaneous tumor growth in nude mice, with marked reductions in tumor volume and weight. | Mol Med Rep. 2021 Dec;24(6):828 |
Nude mice | BT-474 tumor xenografts | Intravenous injection | 5 or 10 mg/kg | Daily for 5 days, followed by an injection every other day for five additional treatments and then a final injection 2 h prior to sacrifice | To evaluate the effect of RO 48-8071 on BT-474 tumor xenografts, RO significantly suppressed tumor growth with no apparent toxicity. | Breast Cancer Res Treat. 2014 Jul;146(1):51-62 |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.86mL 1.77mL 0.89mL |
17.72mL 3.54mL 1.77mL |
|
Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
Tags: Ro 48-8071 | oxidosqualene cyclase (OSC) inhibitor | lanosterol synthase inhibitor | cholesterol biosynthesis inhibitor | lipid metabolism modulator | OSC-targeted small molecule | mevalonate pathway | sterol synthesis | anticancer lipid metabolism | endocrine disruptor | non-statin cholesterol-lowering agent | hepatic cholesterol regulator | oxidosqualene-lanosterol conversion inhibitor | lipid homeostasis regulator | sterol regulatory element-binding protein (SREBP) pathway modulator | 189197-69-1 |
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL